8-K: RadNet Reports Record Q2 Revenue and EBITDA, Raises Guidance

RadNet, Inc. announced record-breaking second quarter financial results for 2026, driven by significant revenue growth and adjusted EBITDA, leading to an upward revision of full-year financial guidance.

Summary

• RadNet reported record quarterly revenue of $622.7 million for Q2 2026, a 25.0% increase from $498.2 million in Q2 2025.
• Total Company Adjusted EBITDA reached a record $99.7 million in Q2 2026, up 22.7% from $81.2 million in Q2 2025.
• Digital Health segment revenue saw substantial growth, increasing 56.5% to $32.4 million in Q2 2026 from $20.7 million in Q2 2025.
• Annual Recurring Revenue (ARR) for Digital Health more than doubled year-over-year, reaching $105.5 million as of June 30, 2026.
• The company revised upwards its full-year 2026 guidance for Imaging Center segment revenue, Adjusted EBITDA, and Free Cash Flow.
• Net Debt to Adjusted EBITDA Ratio was 1.8x as of June 30, 2026, with a cash balance of $726.3 million.
• Net income attributable to RadNet, Inc. common stockholders was $7.5 million ($0.10 per share) for Q2 2026, compared to $14.5 million ($0.19 per share) in Q2 2025, impacted by one-time items.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, record EBITDA, and upwardly revised guidance, indicating robust operational performance and positive future prospects.

Positives

• Record quarterly revenue of $622.7 million for Q2 2026, a 25.0% increase year-over-year.
• Record quarterly Adjusted EBITDA of $99.7 million for Q2 2026, a 22.7% increase year-over-year.
• Significant 56.5% revenue growth in the Digital Health segment to $32.4 million in Q2 2026.
• Digital Health ARR grew by 97.2% year-over-year to $105.5 million as of June 30, 2026.
• Imaging Center Segment Adjusted EBITDA margin improved by 17 basis points to 16.1%.
• Advanced imaging procedural volumes increased by 21.2% year-over-year, with a favorable shift in mix to 29.9%.
• Upward revision of full-year 2026 guidance for Imaging Center segment revenue, Adjusted EBITDA, and Free Cash Flow.
• Strong balance sheet with $726.3 million in cash and a Net Debt to Adjusted EBITDA Ratio of 1.8x.

Negatives

• Digital Health segment Adjusted EBITDA decreased by 27.2% to $2.5 million in Q2 2026 compared to $3.4 million in Q2 2025, due to infrastructure investments.
• Total Company Net Income attributable to common stockholders decreased to $7.5 million in Q2 2026 from $14.5 million in Q2 2025.
• Adjusted Earnings Per Share decreased to $0.29 in Q2 2026 from $0.34 in Q2 2025.
• Total Company Net Loss for the first six months of 2026 was $25.9 million, compared to a net loss of $23.5 million for the same period in 2025.

Risks

• The impact of a pandemic, significant deterioration in the broader economy, or severe acts of nature on the business.
• Availability and terms of capital to fund business expansion and improvements.
• Ability to service indebtedness and remain compliant with debt covenants.
• Changes in general economic conditions nationally and regionally.
• Impact of political environment and healthcare reform on coverage and reimbursement rates.
• Potential for increased bankruptcies among partner physicians or joint venture partners.
• Cybersecurity incidents or other security breaches involving confidential information.
• Risks associated with mergers and acquisitions, including integration and achieving anticipated benefits.

Future Outlook

RadNet has revised upwards its full-year 2026 guidance for the Imaging Center segment, increasing expectations for Revenue, Adjusted EBITDA, and Free Cash Flow. Guidance for the Digital Health segment remains reaffirmed.

Management Comments

• "The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results."
• "Growth was driven by strong increases in aggregate and same center procedural volumes, the contribution from recent acquisitions, a continuing shift in procedural volumes towards advanced imaging and incremental Digital Health sales and licenses of Enterprise Imaging and AI solutions."
• "Within the Imaging Center operating segment, we continue to have success in driving more advanced imaging procedures and increasing advanced imaging capacity through a variety of operating and Digital Health technology initiatives."
• "The Digital Health division continues to make significant progress."
• "On the regulatory front, at the end of July, DeepHealths breast ultrasound AI solution was cleared by the FDA. We expect to implement this solution across RadNets breast imaging centers by year-end and anticipate both Revenue and cost savings contributions in the second half of this year from the roll-out."
• "Our joint venture business continues to grow. As of the end of the second quarter, 157 of our 442 locations (or approximately 36%) were held within health system partnerships."
• "Given the positive trends within the industry and RadNets strong financial performance of the second quarter, we are revising upwards 2026 Imaging Center guidance levels for Revenue, Adjusted EBITDA(1) and Free Cash Flow(2) in anticipation of financial results that we believe will exceed both our original expectations and the amendments we made to the guidance ranges upon releasing first quarter 2026 results in May."

Industry Context

StockSavvy.ai notes that RadNet's performance aligns with broader industry trends favoring advanced imaging and the integration of AI and digital health solutions in healthcare services. The company's strategic focus on these areas appears to be driving significant growth and market share.

Comparison to Industry Standards

• RadNet's revenue growth of 25.0% in Q2 2026 significantly outpaces the general healthcare services sector growth rates, which are typically in the mid-to-high single digits.
• The 22.7% increase in Adjusted EBITDA is also a strong indicator of operational efficiency and pricing power, often exceeding industry averages for similar service providers.
• The shift towards advanced imaging (MRI, CT, PET/CT) to 29.9% of procedural volumes is a key positive trend, as these modalities generally carry higher reimbursement rates and margins compared to routine imaging, a trend observed across leading diagnostic imaging providers.
• The Digital Health segment's ARR growth of 97.2% is exceptional and reflects the increasing adoption of AI and enterprise imaging solutions in healthcare, a segment experiencing rapid innovation and investment across the industry.

Stakeholder Impact

• Shareholders: Positive impact from record revenue, EBITDA, and upwardly revised guidance, suggesting potential for increased shareholder value.
• Employees: Investments in Digital Health headcount may lead to increased employment opportunities in sales, marketing, customer service, and implementation.
• Customers/Patients: Continued shift towards advanced imaging and AI solutions may lead to improved diagnostic accuracy and patient care.
• Partners/Joint Venture Partners: Growth in joint ventures and adoption of DeepHealth solutions by partners like Saint Alphonsus Health System indicates strengthening relationships and shared growth opportunities.

Next Steps

• Implement DeepHealth's FDA-cleared breast ultrasound AI solution across RadNet's breast imaging centers by year-end 2026.
• Continue to grow joint venture business, with 157 of 442 locations held within health system partnerships as of Q2 2026.
• Host a conference call on August 10, 2026, to discuss Q2 2026 financial results.

Key Dates

Recommendation

The filing demonstrates strong operational execution with record revenue and EBITDA, significant growth in key segments like Digital Health, and a favorable shift in procedural mix. The upward revision of full-year guidance, coupled with a solid balance sheet and strategic investments in AI, suggests continued positive momentum and potential for future value creation, warranting a buy recommendation.

Keywords

diagnostic imaging, outpatient imaging centers, Digital Health, AI solutions, revenue growth, Adjusted EBITDA, financial guidance, healthcare technology